Related Experiment Videos

Redd1 inhibits the invasiveness of non-small cell lung cancer cells

Hyeon-Ok Jin1, Sung-Keum Seo, Sang-Hyeok Woo

  • 1Division of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, 215-4 Gongneung-dong, Nowon-gu, Seoul 139-706, Republic of Korea. hyeonok@kirams.re.kr

Insights

The study reveals that Redd1 suppresses non-small cell lung cancer (NSCLC) cell invasion by inhibiting the mTOR pathway. Redd1

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Redd1 is a known negative regulator of mTOR signaling under stress.
  • The precise physiological function of Redd1, particularly in cancer, remains largely undefined.
  • Understanding Redd1's role could offer new therapeutic strategies for lung cancer.

Purpose of the Study:

  • To investigate the role of Redd1 in the invasive behavior of non-small cell lung cancer (NSCLC) cells.
  • To elucidate the molecular mechanisms by which Redd1 influences cancer cell invasiveness.
  • To determine the involvement of the mTOR pathway in Redd1-mediated effects on NSCLC.

Main Methods:

  • Analysis of Redd1 expression levels in NSCLC cell lines with varying invasive potentials (H1299 vs. H460).
  • Experimental manipulation of Redd1 levels through overexpression and siRNA-mediated knockdown.
  • Assessment of cell invasive activity following genetic modifications.
  • Investigation of the mTOR downstream pathway, including knockdown of S6K.

Main Results:

  • Redd1 expression was inversely correlated with the invasive capacity of NSCLC cells.
  • Overexpression of Redd1 significantly reduced H1299 cell invasiveness.
  • siRNA-mediated suppression of Redd1 increased the invasiveness of H460 cells.
  • Knockdown of S6K, an mTOR downstream target, decreased H1299 cell invasiveness.

Conclusions:

  • Redd1 acts as an inhibitor of non-small cell lung cancer cell invasion.
  • The inhibitory effect of Redd1 on NSCLC invasiveness is mediated through the suppression of the mTOR downstream pathway.
  • These findings suggest Redd1 as a potential therapeutic target for reducing NSCLC metastasis.

Related Concept Videos